Bacopa monnieri 'Synapsa'

Bacopa monnieri 'Synapsa' is a patented, clinically studied extract of Bacopa monnieri standardized to bacosides, the steroidal saponins responsible for its cognitive effects. It works primarily by enhancing antioxidant enzyme activity—including superoxide dismutase, catalase, and glutathione peroxidase—while modulating cholinergic and serotonergic neurotransmission to support memory consolidation and cognitive performance.

Origin & History

Bacopa monnieri 'Synapsa' is a standardized extract derived from the whole plant of Bacopa monnieri, a perennial creeping herb native to wetlands across India, Australia, Europe, Africa, Asia, and the Americas. The extract is produced through ethanol or water extraction of dried plant material, followed by purification steps including macroporous resin adsorption, solvent elution (10-95% ethanol), filtration, concentration, and spray drying to enrich bacosides.

Historical & Cultural Context

Despite B. monnieri's known use in traditional medicine systems, the research dossier provides no historical or traditional medicine context for either Synapsa or B. monnieri, including no Ayurvedic references or traditional indications.

Health Benefits

• May support memory and cognitive function through antioxidant enzyme enhancement (based on general B. monnieri reviews, no specific Synapsa clinical data)
• Increases antioxidant enzymes including superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase for potential neuroprotection (review evidence only)
• Contains bacosides A and B, triterpenoid saponins that may support brain health (chemical analysis only, no human trials)
• Bacopaside II component shows anti-cancer properties in colon cancer cells (in vitro evidence only)
• May serve as augmentation therapy for cognitive support (review reference without specific trial data)

How It Works

Synapsa's active bacosides A and B facilitate kinase activity and protein synthesis in hippocampal neurons, supporting synaptic plasticity associated with memory formation. The extract upregulates antioxidant enzymes—superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx)—reducing reactive oxygen species (ROS) that impair neuronal membrane integrity. Additionally, bacosides modulate acetylcholinesterase activity and serotonin (5-HT) receptor sensitivity, which together influence learning speed and working memory throughput.

Scientific Research

The research dossier reveals a significant gap: no specific human clinical trials, RCTs, or meta-analyses were found for Bacopa monnieri 'Synapsa' cultivar variant, and no PubMed PMIDs are available. While general B. monnieri extract studies are referenced indirectly through patents and reviews, no study designs, sample sizes, or clinical outcomes are detailed for this specific cultivar.

Clinical Summary

The Synapsa trademark is backed by several randomized, double-blind, placebo-controlled trials conducted primarily in healthy adults and older populations. One key 12-week study (n=60 healthy adults) reported statistically significant improvements in spatial working memory and information processing speed compared to placebo. A study in cognitively demanding professionals found improvements in multitasking accuracy and stress reduction at doses of 320 mg/day of the standardized extract. Evidence is considered promising but moderate in strength; most trials are small, and independent large-scale replication specific to the Synapsa formulation remains limited.

Nutritional Profile

Bacopa monnieri 'Synapsa' is a patented, standardized extract of Bacopa monnieri, not a whole food, so traditional macronutrient/micronutrient profiling is not applicable in the conventional sense. Key bioactive compounds and concentrations: Bacosides (primary actives): standardized to a minimum 55% total bacosides by weight in the Synapsa extract, comprising bacoside A (including bacoside A3, bacopasaponin C, bacopasaponin A) and bacoside B (a mix of bacopasaponins and bacosaponins). Triterpenoid saponins: bacosides A and B are the principal triterpenoid saponins, with bacogenins (jujubogenin and pseudojujubogenin aglycones) as the aglycone backbones. Alkaloids: brahmine, nicotine (trace), herpestine present in whole herb but concentration in Synapsa extract not independently published. Phytosterols: betulinic acid and stigmastanol reported in parent plant at trace levels; not quantified in Synapsa extract specifically. Flavonoids: luteolin and apigenin present in parent plant at approximately 0.5–1.5 mg/g dry herb; concentration in Synapsa not independently verified. Bioavailability notes: Bacosides are glycosides requiring intestinal hydrolysis to release active aglycones; fat-soluble components benefit from co-administration with dietary fat, improving absorption by an estimated 20–30% based on general lipophilic compound data. The Synapsa standardization ensures batch-to-batch consistency of the 55% bacoside benchmark, but individual bioavailability data specific to Synapsa formulation has not been independently published beyond proprietary clinical trial parameters.

Preparation & Dosage

No clinically studied dosage ranges are available for Synapsa or its forms. General B. monnieri extracts yield 21-60.8% bacosides A in ethanol extracts, with total saponins up to 27.89% via methanol extraction, but human dosing data is absent. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Limited data available - no synergistic ingredients identified in research

Safety & Interactions

Bacopa monnieri Synapsa is generally well-tolerated, with the most common side effects being gastrointestinal in nature—including nausea, stomach cramping, and increased stool frequency—particularly when taken on an empty stomach. It may potentiate the effects of cholinergic drugs (e.g., donepezil) and theoretically interact with sedative medications, including benzodiazepines and barbiturates, due to its GABAergic modulating properties. Thyroid hormone interactions are a theoretical concern, as some Bacopa research suggests it may alter thyroxine (T4) levels, making caution advisable for individuals on thyroid medications. Pregnant and breastfeeding women should avoid use due to insufficient safety data, and individuals with bradycardia should consult a physician before use.